A novel drug, named 'FerriIridium,' can simultaneously help diagnose and treat gastric cancer. The initially weakly active precursor (prodrug), based on an iridium-containing compound, is selectively activated only after reaching the interior of a tumor cell. This is possible because of the higher amount of iron present there, report scientists. Selective activation reduces undesired side effects.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/01/200123114702.htm
No comments:
Post a Comment